Butler Andrew R, Bate Neil, Kiehl Douglas E, Kirst Herbert A, Cundliffe Eric
Biochemistry Department, University of Leicester, Leicester LE1 7RH, UK.
Nat Biotechnol. 2002 Jul;20(7):713-6. doi: 10.1038/nbt0702-713.
The antibacterial properties of macrolide antibiotics (such as erythromycin, tylosin, and narbomycin) depend ultimately on the glycosylation of otherwise inactive polyketide lactones. Among the sugars commonly found in such macrolides are various 6-deoxyhexoses including the 3-dimethylamino sugars mycaminose and desosamine (4-deoxymycaminose). Some macrolides (such as tylosin) possess multiple sugar moieties, whereas others (such as narbomycin) have only single sugar substituents. As patterns of glycosylation markedly influence a macrolide's drug activity, there is considerable interest in the possibility of using combinatorial biosynthesis to generate new pairings of polyketide lactones with sugars, especially 6-deoxyhexoses. Here, we report a successful attempt to alter the aminodeoxyhexose-biosynthetic capacity of Streptomyces fradiae (a producer of tylosin) by importing genes from the narbomycin producer Streptomyces narbonensis. This engineered S. fradiae produced substantial amounts of two potentially useful macrolides that had not previously been obtained by fermentation.
大环内酯类抗生素(如红霉素、泰乐菌素和纳罗霉素)的抗菌特性最终取决于原本无活性的聚酮内酯的糖基化。在此类大环内酯中常见的糖类包括各种6-脱氧己糖,其中有3-二甲基氨基糖,如碳霉糖和去氧氨基糖(4-脱氧碳霉糖)。一些大环内酯(如泰乐菌素)具有多个糖基部分,而其他一些(如纳罗霉素)只有单个糖取代基。由于糖基化模式显著影响大环内酯的药物活性,人们对利用组合生物合成来生成聚酮内酯与糖类(尤其是6-脱氧己糖)的新组合的可能性非常感兴趣。在此,我们报告了一次成功的尝试,即通过导入来自纳罗霉素产生菌纳博讷链霉菌的基因,改变弗氏链霉菌(泰乐菌素的产生菌)的氨基脱氧己糖生物合成能力。这种经过基因工程改造的弗氏链霉菌产生了大量两种以前未通过发酵获得的潜在有用的大环内酯。